Type 3c Diabetes
Type 3c diabetes has, for some time, been included under the umbrella of Type 1 diabetes. But as we move more towards understanding the implications of different causes of diabetes nomenclature is evolving too.
Type 3c diabetes is diabetes caused by other disease/damage of the pancreas. It is often referred to as Pancreatogenic Diabetes.
This class of atypical diabetes includes a number of conditions that may be inherited or acquired, including cystic fibrosis, hemochromatosis, chronic pancreatitis, fibrocalculous pancreatopathy, pancreatic cancer, pancreatectomy, and congenital pancreatic agenesis. In some cases, the disease process underlying the diabetes development in these conditions is incompletely understood.
Please don’t confuse Type 3c with the ‘Type 3’ that has been described referring to insulin resistance in the brain related to dementia. This latter condition is described on another page.
What is Type 3c Diabetes?
Most people are familiar with type 1 and type 2 diabetes, but fewer have heard of type 3c diabetes. Also called pancreatogenic diabetes, this form develops as a consequence of pancreatic disease, surgery, or trauma. Although it shares some features with type 1 diabetes — notably insulin deficiency — it is a distinct condition with unique causes, clinical features, and management challenges.
Type 3c diabetes arises when the pancreas is damaged, leading to loss of both the insulin-producing beta cells and the cells that secrete digestive enzymes. Common causes include:
- Chronic pancreatitis
- Pancreatic surgery or partial pancreatectomy
- Cystic fibrosis
- Haemochromatosis
- Pancreatic cancer or trauma
As a result, people with type 3c diabetes often experience both impaired insulin secretion and impaired production of digestive enzymes (exocrine insufficiency).
Comparing Type 1 with Type 3c Diabetes
Similarities
<insert table>
Differences
<insert table>
Diagnosis Challenges
Type 3c diabetes is often misclassified as type 2 or even type 1 diabetes. Key diagnostic clues include:
- History of chronic pancreatitis, pancreatic surgery, or pancreatic cancer.
- Evidence of exocrine insufficiency (low faecal elastase, need for enzyme replacement).
- Lack of autoimmune markers (negative GAD, IA-2, ZnT8 antibodies).
- Reduced C-peptide but also low glucagon levels.
Management Principles
- Insulin Therapy:
Many individuals eventually require insulin, but initial treatment may involve metformin or other oral agents if residual beta-cell function remains. - Pancreatic Enzyme Replacement Therapy (PERT):
Replacing digestive enzymes improves nutrient absorption, stabilises body weight, and may lead to more predictable blood glucose levels. - Nutritional Support:
High-calorie, nutrient-dense diets may be necessary, with vitamin supplementation (especially fat-soluble vitamins A, D, E, K). - Blood Glucose Monitoring:
Because of unpredictable carbohydrate absorption and variable insulin requirements, frequent monitoring or CGM can be especially helpful. - Hypoglycaemia Prevention:
Education about low glucose symptoms, liberal glucose targets if necessary, and use of CGM with alarms may reduce severe hypoglycaemia risk. - Multidisciplinary Care:
Gastroenterologists, dietitians, endocrinologists, and diabetes educators all play critical roles.
Looking Ahead: Technology and Research
As with type 1 diabetes, CGM and insulin pump therapy can benefit some people with type 3c diabetes, although evidence is still limited. Hybrid closed-loop systems may offer potential, but the lack of glucagon secretion and digestive variability present unique challenges for algorithms designed for type 1 diabetes physiology.
Type 3c diabetes is distinct from both type 1 and type 2 diabetes, yet shares features with each. Recognising its unique cause, higher risk of hypoglycaemia, and the need for pancreatic enzyme replacement is crucial for effective management. By improving awareness and tailoring care, healthcare professionals can help people with type 3c diabetes achieve better outcomes and quality of life.
Page updated: September 2025
